The GLP-1 pill is no longer a pipeline story
Two oral GLP-1s are now FDA-approved for weight management: the Wegovy pill in December 2025 and Foundayo, the first small-molecule GLP-1 built to be swallowed, on April 1, 2026.
For most of the GLP-1 era, starting treatment meant learning to inject. Two approvals have changed that, and both happened while a lot of coverage was still describing oral GLP-1s as something coming later.
The FDA approved a 25 mg oral semaglutide tablet, sold as the Wegovy pill, on December 22, 2025. It reached US pharmacies the following month, and it is the first oral GLP-1 cleared for weight management. It is the same molecule as the injection, so it carries the fasting-and-water routine that oral semaglutide has always required.
Foundayo, the brand name for orforglipron, followed on April 1, 2026. It is a small-molecule drug rather than a peptide, which is why it can be taken once daily with or without food. The FDA describes the decision as its fastest approval of a new molecular entity since 2002. It carries the same boxed warning about thyroid C-cell tumors seen in rodent studies that the injectable GLP-1s carry.
What has not changed is the thing worth scrutinizing. A compounded oral GLP-1 — a pharmacy-made tablet or dissolving strip sold by a cash-pay telehealth seller — is not either of these approved products, whatever molecule is named on it. Low-dose oral semaglutide sold as Rybelsus also remains approved for type 2 diabetes, which is a different indication from weight management.
Go deeper: Read the oral GLP-1 guide, or see the full best GLP-1 providers ranking and this week's price tracker.
This is a dated market observation, current as of Aug 28, 2026, and is health and consumer information for education — not medical advice. Prices and supply status change; confirm at the source. See our disclosure.